Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer (在前列腺癌高风险的男性中补硒治疗对血糖水平没有影响)

• Published in: Journal of diabetes Vol. 5; no. 4; pp. 465 - 470
• Main Authors: Algotar, Amit Mohan, Hsu, Chui-Hseih, Singh, Parminder, Stratton, Steven Paul
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.12.2013; John Wiley & Sons, Inc
• Subjects: Aged; Aged, 80 and over; Blood Glucose - drug effects; Blood Glucose - metabolism; Diabetes; Dietary Supplements; Double-Blind Method; Humans; Male; Middle Aged; Prostate cancer; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Risk; Selenium; Selenium - administration & dosage; selenium supplementation; serum glucose; Studies; 前列腺癌，补硒治疗，血糖; 前列腺癌，补硒治疗，血糖; serum glucose; prostate cancer; selenium supplementation
• ISSN: 1753-0393; 1753-0407; 1753-0407
• DOI: 10.1111/1753-0407.12041

Background Current literature regarding the effect of selenium supplementation on the risk of diabetes is inconclusive. Hence, a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Methods Data were obtained from 699 men participating in a randomized double‐blind placebo‐controlled Phase 3 clinical trial investigating the effects of two doses of selenium (200 and 400 μg/day) compared with placebo on the incidence of prostate cancer. Subjects were followed every 6 months for up to 5 years. Serum glucose levels were obtained every 6 months. Mixed‐effects regression models were used to assess whether the rate of change of serum glucose levels was significantly different in the selenium‐supplemented groups compared with placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Results Of the total 2893 glucose measurements, 734 were performed when the subject had been fasting for ≥8 h. Changes in serum glucose levels during the course of the trial did not differ significantly between the placebo and selenium 200 μg/day (P = 0.98) and 400 μg/day (P = 0.81) groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. Conclusion These results do not support a relationship between selenium supplementation and risk of diabetes. Hence, recommendations regarding selenium supplementation based on increased risk of diabetes seem premature. 摘要 背景 目前的文献对补硒治疗对糖尿病风险的影响尚无定论。因此，我们进行了一项纵向研究，在老年男性中调查了补硒治疗对血糖水平的影响。 方法 所获数据来源于699名男性，他们参与了一项随机、双盲、安慰剂对照的3期临床试验，调查了与安慰剂相比较两种剂量的硒（200与400 µg/日）对前列腺癌发生率的影响。受试者每6个月随访一次，随访时间长达5年。血糖水平每6个月测定一次。使用混合效应模型来评估血糖水平的变化率在补硒治疗组和安慰剂对照组是否有显著性的差异。进行敏感性分析以评估研究结果的稳定性，并使空腹状态所导致的残余偏移的可能性最小化。 结果 在总共2893次血糖测量中，有734次测量时受试者的禁食时间≥8 h。在安慰剂组与200 µg/日（P = 0.98）以及400 µg/日（P = 0.81）的补硒治疗组之间，试验期间的血糖水平变化都没有显著性差异。敏感性分析结果表明，无论是使用全部人群的模型还是只使用空腹受试者血糖数据的模型，结果都具有可比性。 结论 这些结果并不支持补硒治疗与糖尿病风险具有相关性。因此，关于补硒治疗后糖尿病风险增加的结论似乎还下得为时过早。